Shujing Liu

Department of Pathology and Laboratory Medicine, University of Pennsylvania

Affiliated withUniversity of Pennsylvania

Research Area

Cancer Research

Biography

Shujing Liu has not added Biography.
If you are Shujing Liu and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title	2024

Other Publications

Article	Year
IL8 and Cathepsin B as Melanoma Serum Biomarkers. International journal of molecular sciences\| PubMed ID: 21673904	2011
Snail1 mediates hypoxia-induced melanoma progression. The American journal of pathology\| PubMed ID: 21996677	2011
Norcantharidin induces melanoma cell apoptosis through activation of TR3 dependent pathway. Cancer biology & therapy\| PubMed ID: 22123174	2011
MicroRNA-9 up-regulates E-cadherin through inhibition of NF-ÎºB1-Snail1 pathway in melanoma. The Journal of pathology\| PubMed ID: 22131135	2012
Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene\| PubMed ID: 22286766	2012
Loss of microRNA-205 expression is associated with melanoma progression. Laboratory investigation; a journal of technical methods and pathology\| PubMed ID: 22525428	2012
miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1. The American journal of pathology\| PubMed ID: 22982443	2012
The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma. Molecular and cellular biology\| PubMed ID: 24019069	2013
Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 24132921	2013
Exo70 isoform switching upon epithelial-mesenchymal transition mediates cancer cell invasion. Developmental cell\| PubMed ID: 24331928	2013
Generation of folliculogenic human epithelial stem cells from induced pluripotent stem cells. Nature communications\| PubMed ID: 24468981	2014
Direct conversion of mouse and human fibroblasts to functional melanocytes by defined factors. Nature communications\| PubMed ID: 25510211	2014
miR-200c/Bmi1 axis and epithelial-mesenchymal transition contribute to acquired resistance to BRAF inhibitor treatment. Pigment cell & melanoma research\| PubMed ID: 25903073	2015
TR3 is preferentially expressed by bulge epithelial stem cells in human hair follicles. Laboratory investigation; a journal of technical methods and pathology\| PubMed ID: 26707825	2016
Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell reports\| PubMed ID: 27210749	2016
Screening for Neuraminidase Inhibitory Activity in Traditional Chinese Medicines Used to Treat Influenza. Molecules (Basel, Switzerland)\| PubMed ID: 27618892	2016
A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles. Cancer discovery\| PubMed ID: 28899863	2017
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature\| PubMed ID: 28953887	2017
A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 29051322	2018
Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma. Oncotarget\| PubMed ID: 29383148	2017
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature\| PubMed ID: 30089911	2018
A Designer Cross-reactive DNA Immunotherapeutic Vaccine that Targets Multiple MAGE-A Family Members Simultaneously for Cancer Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 30262507	2018
: A Cancer Immunotherapy Review. Frontiers in pharmacology\| PubMed ID: 30410443	2018
Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature\| PubMed ID: 30532003	2019
ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. Cancer discovery\| PubMed ID: 30563872	2019
Loss of Phd2 cooperates with BRAF to drive melanomagenesis. Nature communications\| PubMed ID: 30575721	2018
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nature medicine\| PubMed ID: 30804515	2019
Author Correction: Loss of Phd2 cooperates with BRAF to drive melanomagenesis. Nature communications\| PubMed ID: 30858377	2019
Multispectral photoacoustic imaging for the detection of subclinical melanoma. Journal of surgical oncology\| PubMed ID: 30874312	2019
Stromal inflammatory cells are associated with poorer prognosis in primary cutaneous melanoma. Human pathology\| PubMed ID: 30965022	2019
PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma. JCI insight\| PubMed ID: 32780726	2020
Small extracellular vesicles-based cell-free strategies for therapy. MedComm\| PubMed ID: 34766134	2021
Targeting regulatory T cells for immunotherapy in melanoma. Molecular biomedicine\| PubMed ID: 34806028	2021
Costimulation of γδTCR and TLR7/8 promotes Vδ2 T-cell antitumor activity by modulating mTOR pathway and APC function. Journal for immunotherapy of cancer\| PubMed ID: 34937742	2021
HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8 T-cell infiltration into tumors. Nature communications\| PubMed ID: 35835783	2022
Patient-derived melanoma organoid models facilitate the assessment of immunotherapies. EBioMedicine\| PubMed ID: 37229906	2023
Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity. Cell reports\| PubMed ID: 37805922	2023